Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
Ampio Pharmaceuticals, Inc. (AMPE) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 920 K | -3,815,000 | 2.38 M | 5.74 M | 5.74 M |
| 2022 | -12,039,000 | 1.8 M | 13.59 M | 13.33 M | |
| 2021 | 16 K | -32,967,000 | 11.54 M | 38.83 M | 35.63 M |
| 2020 | 185 K | -16,137,000 | 5.37 M | 22.88 M | 18.49 M |
| 2019 | -5,063,000 | 7.56 M | 14 M | 8.25 M |